Ser138

Site Information
AMBIGUOUS SITES: CTAGE15 (human): , CTAGE6 (human): , CTAGE8 (human): , CTAGE9 (human): , MIA2 (human): , MIA2 iso7 (human):
TCEKLNRsNsELEDE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 27446829

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 )
Disease tissue studied:	breast cancer ( 3 , 9 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 9 ) , non-small cell lung cancer ( 9 ) , lymphoma ( 4 ) , Burkitt's lymphoma ( 4 ) , follicular lymphoma ( 4 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 5 ) , BJAB (B lymphocyte) ( 4 ) , breast ( 1 ) , BT-20 (breast cell) ( 9 ) , BT-474 (breast cell) ( 3 ) , BT-549 (breast cell) ( 9 ) , Calu 6 (pulmonary) ( 9 ) , FL-318 (B lymphocyte) ( 4 ) , H2009 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H2887 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC1359 (pulmonary) ( 9 ) , HCC1937 (breast cell) ( 9 ) , HCC2279 (pulmonary) ( 9 ) , HCC366 (pulmonary) ( 9 ) , HCC4006 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 9 ) , HeLa (cervical) ( 8 , 10 , 11 ) , HOP62 (pulmonary) ( 9 ) , Jurkat (T lymphocyte) ( 6 ) , K562 (erythroid) ( 8 ) , LCLC-103H (pulmonary) ( 9 ) , LOU-NH91 (squamous) ( 9 ) , MCF-7 (breast cell) ( 9 ) , MDA-MB-231 (breast cell) ( 9 ) , MDA-MB-468 (breast cell) ( 9 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H1568 (pulmonary) ( 9 ) , NCI-H157 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H2172 (pulmonary) ( 9 ) , NCI-H322 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H520 (squamous) ( 9 ) , NCI-H647 (pulmonary) ( 9 ) , PC9 (pulmonary) ( 9 )

Upstream Regulation
Treatments:	AZD1152 ( 10 ) , ZM447439 ( 10 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
4	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
5	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
8	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
9	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
10	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
11	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info